The stakeholders who spoke at the close-out ceremony of Safety and Anti-microbial Resistance of Mass Administration of Azithromycin, SARMAAN, pilot project in Abia State, expressed satisfaction at ...

Under the terms of the agreement, Sandoz has exclusive commercial rights for a biosimilar of ipilimumab in Australia, Canada, Europe, Japan and the US. The core sequence patent for ipilimumab ...

MONDAY, April 21, 2025 (HealthDay News) -- For uncomplicated urogenital gonorrhea, gepotidacin, which inhibits bacterial DNA replication, is noninferior to ceftriaxone plus azithromycin ...

“Our top priority at Sandoz is to develop affordable biosimilars for high-quality biologics and ensure that as many patients as possible have access to them. Introducing the 15mg concentration of our ...

LONDON (Reuters) -The chief executive of generic drugmaker Sandoz said a proposal by the CEOs of Novartis and Sanofi to introduce a Europe-wide list price for new medicines is "deeply flawed" and ...

This means that Medicare may typically cover antibiotics, such as azithromycin. With Original Medicare (Part A and Part B), you can purchase stand-alone Part D plans from Medicare-approved private ...

Three clinical trials have examined the efficacy and safety of single dose azithromycin (30 mg/kg) in children with uncomplicated acute otitis media (AOM). In the first trial, a small pilot study ...

LONDON (Reuters) -The chief executive of generic drugmaker Sandoz (SIX:SDZ) said a proposal by the CEOs of Novartis (SIX:NOVN) and Sanofi (NASDAQ:SNY) to introduce a Europe-wide list price for new ...

As the global leader in generic and biosimilar medicines, Sandoz is committed to its purpose of "pioneering access for patients" and has benefited over 900 million patients worldwide with ...

Azithromycin has been widely evaluated for its efficacy against COVID-19. The study by Timothy S C Hinks and colleagues1 adds value to the current literature, and we would like to share our comments.

Investing.com -- Sandoz (SIX:SDZ) shares slid around 3% Wednesday after the Swiss drugmaker reported first-quarter 2025 sales that came in 5% below company-compiled consensus. Excluding the impact ...